% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • amarildose amarildose May 13, 2013 9:18 AM Flag

    Elan buys into four GSK programs


    Theravance and Elan have entered into a $1 billion royalty participation agreement through which Elan will purchase interest in potential future payments related to four respiratory programs partnered with GlaxoSmithKline.

    Under the terms of the agreement, Elan will make a one-time cash payment to Theravance for a 21% participation interest in potential future royalty payments from the four programs—RELVAR™ or BREO™ ELLIPTA™, ANORO™ ELLIPTA™, MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist) monotherapy (GSK961081/MABA '081), and VI monotherapy, all developed through the LABA collaboration with GSK—when, as, and if received. Theravance is entitled to receive royalties from GSK of 15% of the first $3 billion combined annual global net sales, plus 5% of such sales above $3 billion.

    This topic is deleted.
2.06+0.08(+4.04%)Oct 2 4:00 PMEDT